Net revenue from operations in Q4FY21 was reported at Rs77.54cr, higher by 3.03% over previous fiscal’s same period net revenue from operations of Rs75.26cr. Company reported an EBITDA of Rs16.74cr in Q4FY21, rise of 28.25% as compared to Rs13.05cr in the corresponding period last year.
EPS for Q4FY21 was at Rs5.92 per share as compared to Rs4.62 in the corresponding period last year. Company has recommended a dividend of 15% - Rs1.50 per share on the face value of Rs10 per share.
During the fiscal, promoter group of Lincoln Pharmaceuticals Ltd increased holding in the company to 37.25% - rise of 4.9% (490 bps) from 32.36% as of 31 March 2020.
Promoter group bought 9.8 lakh shares from the secondary market during the year. Backed by improvement in the company’s financial risk profile, steady growth in scale & margins, healthy profitability, rating agency ICRA has upgraded the company’s long-term and short-term bank facilities to A and A1 respectively.
Commenting on the results and performance, Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, "Company’s performance during the quarter and full year has been quite robust and considering that we have recommended a dividend of Rs1.50 per share. Company is growing strength to strength, delivering robust operational and financial performance maintaining healthy growth in revenue, margins and profitability. We expect the growth momentum to continue in coming years. Our strategic growth initiatives, product and geographical expansion, operational efficiency are likely to maximise value for all stakeholders in the near to medium term.”
Company is witnessing good traction in the export business, which is expected to get further boost once EU operations begins. Company plans to enter the EU markets in FY22 with its dermatology, gastro and pain management products. Company currently exports to more than 60 countries and plans to expand to 90 plus countries.
For the next phase of growth, the company is building a strong portfolio in lifestyle and chronic segment especially dermatology, gastro and pain management to complement its strong presence in acute segment.
On Wednesday morning trade, Lincoln Pharmaceuticals was trading at Rs298.25 apiece up by Rs2.1 or 0.71% on Sensex.